Global Blood Therapeutics (GBT) broke out to new highs last week and remains strong today. Let's check out the charts of this clinical-stage biopharmaceutical company.
More from Investing
This action is primarily caused by poor positioning, rather than a sudden improvement in fundamentals.
The process of dealing with a delisted stock is painful for individual investors and impossible for many institutional investors.
Investors are cheering the slowing pace of inflation's increase, but prices are still way up, which means the Fed is going to continue to take liquidity out of the system.